XML 80 R69.htm IDEA: XBRL DOCUMENT v3.21.2
Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2020
shares
Sep. 30, 2020
shares
Jul. 31, 2018
USD ($)
day
$ / shares
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Debt Instrument [Line Items]                  
Deferred income taxes         $ (180,000) $ (204,000)      
Accrued interest         1,750,000        
Long-term debt         180,172,000   $ 171,882,000    
Convertible debt                  
Debt Instrument [Line Items]                  
Long-term debt         176,788,000   168,147,000    
Notes payable                  
Debt Instrument [Line Items]                  
Long-term debt         $ 3,328,000   3,655,000    
Precigen ActoBio Inc. | Convertible debt | Harvest Intrexon Enterprise Fund I, LP                  
Debt Instrument [Line Items]                  
Debt instrument, interest rate, stated percentage                 3.00%
Interest expense       $ 147,000   $ 616,000      
Trans Ova Genetics, LC | Notes payable | American State Bank                  
Debt Instrument [Line Items]                  
Debt instrument, interest rate, stated percentage         3.95%        
Long-term debt         $ 3,328,000        
Debt instrument, periodic payment         39,000        
Harvest Intrexon Enterprise Fund I, LP | Precigen ActoBio Inc.                  
Debt Instrument [Line Items]                  
Aggregate principal amount                 $ 30,000,000
3.5% Convertible Notes Due 2023                  
Debt Instrument [Line Items]                  
Aggregate principal amount     $ 200,000,000   $ 200,000,000        
Proceeds from long-term debt, net of issuance costs     193,958,000            
Debt issuance costs     $ 6,042,000            
Debt instrument, interest rate, stated percentage     3.50%   3.50%        
Conversion rate     58.6622            
Principal amount used in conversion     $ 1,000            
Conversion price (in usd per share) | $ / shares     $ 17.05            
Debt instrument redemption price, percentage     100.00%            
Carrying value of convertible debt     $ 143,723,000   $ 176,788,000   $ 168,147,000    
Equity component of convertible debt, net of issuance costs and deferred taxes     50,235,000            
Deferred income taxes     $ 13,367,000            
Effective interest rate on convertible notes         11.02%        
Convertible notes, unamortized discount and issuance costs         $ 23,212,000        
3.5% Convertible Notes Due 2023 | Minimum                  
Debt Instrument [Line Items]                  
Common stock price trading days | day     20            
Common stock price consecutive trading days | day     30            
Percentage of common share price over conversion price for conversion     130.00%            
3.5% Convertible Notes Due 2023 | Maximum                  
Debt Instrument [Line Items]                  
Common stock price trading days | day     5            
Common stock price consecutive trading days | day     5            
Debt instrument redemption price, percentage     98.00%            
ActoBio Notes                  
Debt Instrument [Line Items]                  
Debt conversion, converted instrument, shares issued (in shares) | shares   6,293,402              
Merck Convertible Note                  
Debt Instrument [Line Items]                  
Aggregate principal amount               $ 25,000,000  
Debt conversion, converted instrument, shares issued (in shares) | shares 6,758,400